NCT06769217View on ClinicalTrials.gov

Clinical Investigation for Everolimus Drug Eluting Stent

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

888

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

November 8, 2024

Study Completion Date

November 1, 2025

Conditions
Coronary Arterial Disease (CAD)
Interventions
DEVICE

Drug Eluting Coronary Stent

The Drug Eluting Coronary stent is indicated for the treatment of de novo coronary artery lesions in patients with symptomatic ischemic heart disease.

Trial Locations (3)

390007

Baroda Heart Institute & Research Centre, Vadodara

Unknown

Grandmed Lubuk Pakam Hospita, Tanjung Morawa

Primaya Tangerang, Jakarta

All Listed Sponsors
lead

Frisch Medical Device Private Limited

INDUSTRY